CompletedNot Applicable

Medical Marijuana in the Pediatric Central Nervous System Tumor Population

United States19 participantsStarted 2016-01-15

Plain-language summary

This study proposes to do a prospective observational cohort study evaluating the quality of life (QOL) of children with Central Nervous System (CNS) tumors and their families who choose to self-medicate with marijuana-derived products while undergoing treatment at Children's Hospital Colorado (CHCO).

Who can participate

Age range2 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 2 years and \< 18 years at the time of study enrollment.
✓. Parents/legal guardian(s) that will be completing the questionnaires must sign consent. There are no age parameters for parent/legal guardians' participation on study.
✓. Patients must have a diagnosis of central nervous system (brain or spinal) tumor
✓. Patients must be ONE of the following:
✓. Interest in marijuana use has been discussed by the patient or parents.
✓. Patient has not used any marijuana products or synthetics in the last 14 days (a washout period of 14 days is permitted for those interested in participating on this study)
✓. An exception to this rule is if patients took their first dose within 72 hours of signing consent. These patients will be eligible for study without going through a washout period.

Exclusion criteria

✕. Does not meet inclusion criteria
✕. Use (or planned use) of synthetic marijuana products as sole cannabinoid therapy

What they're measuring

Overall Quality of Life

Timeframe: 1 year

Trial details

NCT IDNCT03052738

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-06-30

View on ClinicalTrials.gov More Central Nervous System Tumor trials